Target intelligence / Profile preview

Urinary tract microbiome

Molecular classification
Other
01

Overview

The concept of **urinary tract flora**—more accurately called the *urinary tract microbiome*—refers to the diverse community of **microorganisms** (predominantly bacteria) that inhabit the urinary tract, including the bladder and urethra, in both health and disease. Once thought to be sterile, the urinary tract contains resident microbial populations distinct from the gut or vaginal microbiomes. The core genera frequently include **Lactobacillus, Streptococcus, Corynebacterium, Gardnerella, Prevotella, and Escherichia**, among others. The composition varies widely by sex, hormonal status, age, and health, with Lactobacillus being dominant in healthy females of reproductive age. Dysbiosis—an imbalance in this microbial community—has been implicated in urinary tract infections, kidney stones, incontinence, and possibly cancer, making its composition a key factor in urinary health. While the *urinary tract microbiome* is not a single therapeutic target like a receptor or enzyme, emerging therapies include modulation with antibiotics, probiotics, or fecal microbiota transplantation to restore a balanced microbiome and combat recurrent infection or other pathology[1][2][3][4][6][7]. Note: - The term "Urinary tract flora" does not refer to a discrete molecular target, but rather to a **complex ecological community**. Thus, it is not considered a "therapeutic target" in the conventional sense of receptor, enzyme, or gene, and **the query as stated is incorrect for target curation purposes**[6][4]. - The proper scientific term is "Urinary tract microbiome" or "urobiome." - No canonical abbreviation is established; “UT microbiome” or “urobiome” are sometimes informally used. - The urinary microbiome is increasingly seen as a modifiable factor affecting urologic disease, but it cannot be targeted like a single protein or enzyme. - For structured databases of drug targets, this should be classified as “not a valid molecular target.”

Other names
urinary microbiotaurinary floraurobiome
02

Mechanism of action

Antibiotic-induced depletion or alteration of microbial communities; Probiotic colonization to restore or enhance beneficial taxa; FMT to restore microbial diversity and resist uropathogen colonization

03

Biological functions

Maintenance of mucosal homeostasisImmune modulationColonization resistance against uropathogensUrine pH regulationPotential influence on urolithiasis (kidney stones)Metabolite production
04

Disease associations

Infection (especially urinary tract infection)Other (e.g., kidney stone disease, urinary incontinence, bladder cancer)
05

Safety considerations

Antibiotic-driven dysbiosis leading to loss of protective flora and increased infection or stone riskEmergence of multidrug-resistant organismsImmune reactions to bacteriotherapy or FMT
06

Interacting drugs

Antibiotics (e.g., those targeting Escherichia coli, Proteus mirabilis, Klebsiella pneumoniae)

2 more in the full profile.

07

Biomarkers

Relative abundance of Lactobacillus spp. (especially L. crispatus) as a marker for healthPresence or overgrowth of Gardnerella, Escherichia coli, Proteus, or Klebsiella as indicators of dysbiosis or infection

Beyond the preview

Go deeper on Urinary tract microbiome.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Urinary tract microbiome.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call